Cited by 2,051Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record.

Cancer Immunotherapy

Couzin-Frankel, Jennifer·2013·Science

Open this paper in CoChat — free account

Abstract

This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.

Integrity signals

Registry

Crossref · 10.1126/science.342.6165.1432

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 701–800 of 1,000

Recent Advances on NIR‐II Light‐Enhanced Chemodynamic Therapy
Wu, G., Tan, X., & Yang, Q. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303451 · Cited by 38
Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system
Calvillo‐Rodríguez, K. M., Lorenzo-Anota, H. Y., Rodrı́guez-Padilla, C., Martínez‐Torres, A. C., & Scott‐Algara, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294434 · Cited by 37
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors
Gu, Y., & Zhao, Q. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00734-w · Cited by 38
Metal-based immunogenic cell death inducers for cancer immunotherapy
Zou, J. X., Chang, M. R., Kuznetsov, N. A., Kee, J. X., Babak, M. V., & Ang, W. H. (2025) · Chemical Science · doi:10.1039/d4sc08495k · Cited by 42
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis
Yang, Y., Pang, Z., Ding, N., Dong, W., Ma, W., Li, Y., Du, J., & Liu, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.11291 · Cited by 36
“The checkpoint immunotherapy has been increasingly understood and used to unleash the immune system to fight against cancer [1].”
Background
Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission
Mould, R. C., van Vloten, J. P., AuYeung, A. W. K., Karimi, K., & Bridle, B. W. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0316 · Cited by 36
Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors
Nie, Y., Yang, D., Trivett, A. L., Han, Z., Xin, H., Chen, X., & Oppenheim, J. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-14655-8 · Cited by 33
The Roles of Glycodelin in Cancer Development and Progression
Cui, J., Liu, Y., & Wang, X. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01685 · Cited by 36
“In the past decades, immunotherapy has become the main breakthrough in cancer therapy by overcoming cancer immune evasion (105).”
Background
P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer
Farzad, N., Barati, N., Momtazi‐Borojeni, A. A., et al. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1576702 · Cited by 36
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls
Cho, S. Y., Huff, D. T., Jeraj, R., & Albertini, M. R. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.06.001 · Cited by 37
“Issues that need to be addressed in these follow-up FDG PET/CT studies include: (1) prognostic value of baseline FDG PET tumor burden, (2) optimal early imaging time point as an early biomarker of response to therapy, (3) importance and value of an FDG PET “flare” phenomenon on early imaging, (4) how new FDG avid meta…”
Background
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 37
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
Zhang, D., Shah, N. J., Cook, M. R., Blackburn, M. J., Serzan, M. T., Advani, S., Potosky, A. L., Madhavan, S., Belouali, A., Atkins, M. B., et al. (2021) · Cancers · doi:10.3390/cancers13236109 · Cited by 37
The onset of adaptive immunity in the mouse model of tuberculosis and the factors that compromise its expression
Robinson, R., Orme, I. M., & Cooper, A. M. (2015) · Immunological Reviews · doi:10.1111/imr.12259 · Cited by 36
Use of adjuvants for immunotherapy
Circelli, L., Tornesello, M. L., Buonaguro, F. M., et al. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1321725 · Cited by 36
“The concept of cancer immunotherapy is based on using the immune system to attack the tumor cells targeting tumor-specific antigens.(1,2) This can be achieved using passive and/or active strategies.”
Background
Progress in the Regulation of Immune Cells in the Tumor Microenvironment by Bioactive Compounds of Traditional Chinese Medicine
Chen, Y., Fan, W., Zhao, Y., Liu, M., Hu, L., & Zhang, W. (2024) · Molecules · doi:10.3390/molecules29102374 · Cited by 35
Trial watch: Naked and vectored DNA-based anticancer vaccines
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026531 · Cited by 38
Current and Future Approaches in the Management of Non–Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
Matikas, A., Mistriotis, D., Georgoulias, V., & Kotsakis, A. P. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.013 · Cited by 34
Immune checkpoints
Chawla, A., Philips, A. V., Alatrash, G., & Mittendorf, E. A. (2014) · OncoImmunology · doi:10.4161/onci.28325 · Cited by 35
“Cancer Immunotherapy was named Science magazine’s Breakthrough of the Year in 2013.(1) This recognition was largely driven by the success of ipilimumab, the monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed on activated CD8 T cells.”
Background
Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells
Fedorov, V. D., Sadelain, M., & Kloss, C. C. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000040 · Cited by 35
Immunomodulation in cancer
Hegmans, J. P., & Aerts, J. G. J. V. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.06.007 · Cited by 35
Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients
Yuan, C., & Wang, Q. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1851-2 · Cited by 36
“Selected as “Breakthrough of the Year 2013” by the editors of Science Magazine [30], the immune checkpoint inhibitor was one type of immunotherapy, and it could block the co-inhibitory molecules expressed on T cells; herein, unleash brakes on T cells and generates durable anti-cancer effect.”
Background
Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells
Sawasdee, N., Thepmalee, C., Sujjitjoon, J., Yongpitakwattana, P., Junking, M., Poungvarin, N., Yenchitsomanus, P., & Panya, A. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106006 · Cited by 34
Dissemination and Implementation of Palliative Care in Oncology
FERRELL, B. R., Chung, V. M., Koczywas, M., & Smith, T. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.18.01766 · Cited by 35
Biodegradable pH-responsive amorphous calcium carbonate nanoparticles as immunoadjuvants for multimodal imaging and enhanced photoimmunotherapy
Wang, M., Zhou, B., Wang, L., Zhou, F., Smith, N., Saunders, D., Towner, R. A., Song, J., Qu, J., & Chen, W. R. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01453b · Cited by 36
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
Sun, C., Cheng, Y., Liu, X., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.04.007 · Cited by 35
New tools for immunologists: models of lymph node function from cells to tissues
Ozulumba, T., Montalbine, A. N., Ortiz-Cárdenas, J. E., & Pompano, R. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183286 · Cited by 34
Rhizopus nigricans polysaccharide activated macrophages and suppressed tumor growth in CT26 tumor-bearing mice.
Wei, Z., Chen, G.-C., Zhang, P.-Y., Zhu, L., Zhang, L.-N., & Chen, K.-S. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.06.076 · Cited by 35
Regulating the Obesity-Related Tumor Microenvironment to Improve Cancer Immunotherapy
Fang, H., Wu, Y. D., Chen, L., Cao, Z., Deng, Z., Zhao, R., Zhang, L., Yang, Y., Liu, Z., & Chen, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c11159 · Cited by 33
Antigen‐Capturing Dendritic‐Cell–Targeting Nanoparticles for Enhanced Tumor Immunotherapy Based on Photothermal‐Therapy–Induced In Situ Vaccination
Li, Y., Luo, Y., Hou, L., Huang, Z., Wang, Y., & Zhou, S. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202871 · Cited by 36
Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy
Yang, J., Yang, K., Du, S., Luo, W., Wang, C., Liu, H., Liu, K., Zhang, Z., Gao, Y., Han, X., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202306863 · Cited by 34
Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications
Rezazadeh‐Gavgani, E., Majidazar, R., Lotfinejad, P., Kazemi, T., & Shamekh, A. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70196 · Cited by 46
Immunotherapy for prostate cancer: False promises or true hope?
Rekoske, B. T., & McNeel, D. G. (2016) · Cancer · doi:10.1002/cncr.30250 · Cited by 35
Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms
Jahangir, A., Chandra, D., Quispe‐Tintaya, W., Singh, M., Selvanesan, B. C., & Gravekamp, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342025 · Cited by 35
Insights into CD47/SIRPα axis-targeting tumor immunotherapy
Zhang, X., Fan, J., & Ju, D. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby006 · Cited by 34
Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer
Wu, Z., Yang, L., Shi, L., Hu, S., Shi, P.-C., Yang, T., Fan, R., Jiang, T., & Song, J. (2019) · BioMed Research International · doi:10.1155/2019/8014627 · Cited by 34
“Tumor immunotherapy was listed as one of the top ten scientific breakthroughs by Science magazine in 2013 [4].”
Background
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review
Yatoo, M. I., Hamid, Z., RATHER, I. A., Nazir, Q. U. A., Bhat, R. A., Haq, A. U., Magray, S. N., Haq, Z. U., Sah, R., Tiwari, R., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1871295 · Cited by 36
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
“Indeed, checkpoint inhibition, which was described as “breakthrough of the year 2013” [5], has also shown to be able to control melanoma in a long-term fashion [4].”
Current status and future perspective of immune checkpoint inhibitors in colorectal cancer
Zhou, C., Cheng, X., & Tu, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.023 · Cited by 35
Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer
Hirani, P., Gauthier, V., Allen, C. E., Wight, T. N., & Pearce, O. M. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.712807 · Cited by 32
Self‐Splittable Transcytosis Nanoraspberry for NIR‐II Photo‐Immunometabolic Cancer Therapy in Deep Tumor Tissue
Wang, L., Jiang, W., Su, Y., Zhan, M., Peng, S., Liu, H., & Lu, L. (2022) · Advanced Science · doi:10.1002/advs.202204067 · Cited by 34
Advances of Electroporation-Related Therapies and the Synergy with Immunotherapy in Cancer Treatment
Gong, X., Chen, Z., Hu, J. J., & Liu, C. (2022) · Vaccines · doi:10.3390/vaccines10111942 · Cited by 42
Recent progress in cancer immunotherapy: Overview of current status and challenges
Darvishi, M., Tosan, F., Nakhaei, P., Manjili, D. A., Kharkouei, S. A., Alizadeh, A. M., Ilkhani, S., Khalafi, F., Zadeh, F. A., & Shafagh, S.-G. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154241 · Cited by 35
Gene Therapy Approaches Against Cancer Using in Vivo and ex Vivo Gene Transfer of Interleukin-12
Hernández-Alcoceba, R., Poutou, J., Ballesteros-Briones, M. C., & Smerdou, C. (2016) · Immunotherapy · doi:10.2217/imt.15.109 · Cited by 33
Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity
Luo, X., Liu, M., Hu, L., Qiu, Q., Liu, X., Li, C., Lu, M., Liu, Y., Zhang, T., Zhou, S., et al. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.021 · Cited by 34
Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
Liu, H., Li, Y., Li, J., Zhang, Q., Wu, J., Li, X., Meng, L., Cao, S., & Li, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199031 · Cited by 34
“Encouragingly, the implementation of cancer immunotherapy has provided speci ﬁ c cancer patients with prolonged survival bene ﬁ ts, clinical recoveries, and the recognition of this achievement as one of the “ Top 10 Scienti ﬁ c Breakthroughs ” by Science magazine in 2013 (Couzin-Frankel, 2013).”
Background
Advances in mesoporous silica nanoparticles as carriers for drug delivery and other biomedical applications
Grini, M. I., Benbayer, C., Saïdi‐Besbes, S., & Elaı̈ssari, A. (2025) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2025.113603 · Cited by 34
Potential Trade-Offs of Proposed Cuts to the US National Institutes of Health
Jalali, M. S., & Hasgül, Z. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.2228 · Cited by 33
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
Schreiner, J., Thommen, D. S., Herzig, P., Bacac, M., Klein, C., Roller, A., Belousov, A., Levitsky, V., Savic, S., Moersig, W., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1062969 · Cited by 33
“ous clinical benefits, cancer immunotherapy is now emerging as a broadly applicable therapeutic option for cancer treatment.(1) Several strategies can be employed to overcome T-cell dysfunction and”
Background
Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells
Tan, M. P., Dolton, G. M., Gerry, A. B., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12828 · Cited by 33
Reverse geroscience: how does exposure to early diseases accelerate the age‐related decline in health?
Kohanski, R. A., Deeks, S. G., Gravekamp, C., Halter, J. B., High, K. P., Hurria, A., Fuldner, R., Green, P. A., Huebner, R. E., Macchiarini, F., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13297 · Cited by 34
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies
Hegde, U. P., & Mukherji, B. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2007-x · Cited by 33
Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology
Ait-Belkacem, R., Bol, V., Hamm, G. R., Schramme, F., den Eynde, B. J. V., Poncelet, L., Pamelard, F., Stauber, J., & Gomes, B. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217712659 · Cited by 34
Novel tools to assist neoepitope targeting in personalized cancer immunotherapy
Saini, S. K., Rekers, N. H., & Hadrup, S. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx544 · Cited by 33
Towards Breast Cancer Vaccines, Progress and Challenges
Behravan, J., Razazan, A. P., & Behravan, G. (2019) · Current Drug Discovery Technologies · doi:10.2174/1570163815666180502164652 · Cited by 33
Protein‐Engineered Biomaterials for Cancer Theranostics
Liu, X., Wang, C., & Liu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800913 · Cited by 34
Deciphering the Role of Regulatory CD4 T Cells in Oral and Oropharyngeal Cancer: A Systematic Review
O’Higgins, C., Ward, F. J., & Eid, R. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00442 · Cited by 33
“It was therefore not surprising that cancer immunotherapy was named the scientific breakthrough of the year in 2013 (4).”
Background
Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials
Advani, S., & Kopetz, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25441 · Cited by 35
Modeling immune cell behavior across scales in cancer
Makaryan, S. Z., Cess, C. G., & Finley, S. D. (2020) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1484 · Cited by 33
All-Trans Retinoic Acid Stimulates Viral Mimicry, Interferon Responses and Antigen Presentation in Breast-Cancer Cells
Bolis, M., Paroni, G., Fratelli, M., Vallerga, A., Guarrera, L., Zanetti, A., Kurosaki, M., Garattini, S. K., Gianni’, M., Lupi, M., et al. (2020) · Cancers · doi:10.3390/cancers12051169 · Cited by 37
“The discovery that tumors tend to escape immune surveillance modulating immune checkpoints [11] has led to the renaissance of immunotherapy for the personalized treatment of different types of tumors [12,13].”
Overcoming biological barriers to improve solid tumor immunotherapy
Ukidve, A., Cu, K., Kumbhojkar, N., Lahann, J., & Mitragotri, S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00923-8 · Cited by 33
Tissue Multiplex Analyte Detection in Anatomic Pathology – Pathways to Clinical Implementation
Wharton, K. A., Wood, D., Manesse, M., Maclean, K. H., Leiß, F., & Żuraw, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.672531 · Cited by 35
“…oncology research and clinical practice while revealing the importance of endogenous immune “checkpoints” such as PD-L1 and CTLA4 that prevent cytotoxic T lymphocytes in the tumor microenvironment (TME) from targeting a variety of hematological and solid malignancies (Couzin-Frankel, 2013).”
Background
Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists
Xing, D. T., Khor, R., Gan, H. K., Wada, M., Ermongkonchai, T., & Ng, S. P. (2021) · Cancers · doi:10.3390/cancers13225716 · Cited by 33
Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy
Ni, Q., Xu, F., Wang, Y., Li, Y., Qing, G., Zhang, Y., Zhong, J., Li, J., & Liang, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.003 · Cited by 33
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment
Andrés, M. S., Ramalingam, S., Rosen, S. D., Baksi, J. A., Khattar, R. S., Kirichenko, Y. Y., Young, K., Yousaf, N., Okines, A. F. C., Huddart, R. A., et al. (2022) · Cardio-Oncology · doi:10.1186/s40959-022-00147-w · Cited by 35
Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody
Sasaki, M., Tanaka, M., Kojima, Y., Nishie, H., Shimura, T., Kubota, E., & Kataoka, H. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.12.009 · Cited by 34
The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma
Pessina, S., Cantini, G., Kapetis, D., Cazzato, E., Ianni, N. D., Finocchiaro, G., & Pellegatta, S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1108513 · Cited by 33
Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10
Goto, K., Arai, J., Stephanou, A., & Kato, N. (2018) · Oncotarget · doi:10.18632/oncotarget.24568 · Cited by 33
Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study
Nikpoor, A. R., Jaafari, M. R., Zamani, P., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118492 · Cited by 33
Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity
Baiden-Amissah, R. E. M., & Tuyaerts, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143586 · Cited by 30
Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma
Li, Y., Yang, B., Miao, H., Liu, L., Wang, Z., Jiang, C., Yang, Y., Qiu, S., Li, X., Geng, Y., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000028 · Cited by 32
“[45,46] In this study, we established a subcutaneous tumor model in NOD-SCID mice and injected human PBMC and JBSNF-000088.”
Method
How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia
Ruella, M., & Gill, S. I. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1009888 · Cited by 32
“Immunotherapy was the ‘breakthrough of the year’ in 2013, [1], occurring on a background of multiple reports of novel strategies that harness the power of the immune system against cancer in patients with an otherwise poor prognosis [2,3].”
Background
Hostile Takeover: Glioma Stem Cells Recruit TAMs to Support Tumor Progression
Shi, Y., Ping, Y., Zhang, X., & Bian, X. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.02.008 · Cited by 33
“The success of immunotherapeutic antibodies directed against cytotoxic T lymphocyte antigen4 (CTLA-4) and programmed death-1 (PD-1) has proved the potential of cancer immunotherapy in melanoma and other Elsevier Inc. tumor types (Couzin-Frankel, 2013).”
Background
Potentiality of immunotherapy against hepatocellular carcinoma
Tsuchiya, N. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i36.10314 · Cited by 33
Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells
Xiang, B., Baybutt, T. R., Berman-Booty, L. D., Magee, M. S., Waldman, S. A., Alexeev, V. Y., & Snook, A. E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1502672 · Cited by 32
Immunotherapy as an Option for Cancer Treatment
Rusch, T., Bayry, J., Werner, J., Shevchenko, I., & Bazhin, A. V. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0491-5 · Cited by 35
“…as well as other investigators, different strategies for cancer immunotherapy have been proposed, trying to combine boosting the immune response against tumors with shifting the balance of immune editing towards elimination, away from escape and equilibrium (Couzin-Frankel 2013; Kalbasi et al.”
Background
The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells
Guittard, G. C., Dios‐Esponera, A., Palmer, D. C., Akpan, I. O., Barr, V. A., Manna, A. K., Restifo, N. P., & Samelson, L. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-23549-2 · Cited by 30
Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase
Hua, S., Chen, F., Xu, G., & Gou, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.063 · Cited by 33
CAR T Cell Therapy Progress and Challenges for Solid Tumors
Stern, L. A., Jönsson, V. D., & Priceman, S. J. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_11 · Cited by 32
Tryptophan 2,3‐dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma
Sumitomo, M., Takahara, K., Zennami, K., Nagakawa, T., Maeda, Y., Shiogama, K., Yamamoto, Y., Muto, Y., Nukaya, T., Takenaka, M., et al. (2021) · Cancer Science · doi:10.1111/cas.14797 · Cited by 32
Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy
Wang, F., Ye, W., Wang, S., He, Y., Zhong, H., Wang, Y., Zhu, Y., Han, J., Bing, Z., Ji, S., et al. (2021) · Neoplasia · doi:10.1016/j.neo.2021.01.001 · Cited by 34
Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy
Li, B., & Yang, L. (2021) · Nutrients · doi:10.3390/nu13051633 · Cited by 34
Recent Progress in the Design and Medical Application of In Situ Self-Assembled Polypeptide Materials
Wang, T., Xia, Y., Gao, J., Xu, D., & Han, M. Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050753 · Cited by 33
“Nevertheless, the occurrence of tumor resistance is the result of suppressed immune system in the tumor site, therefore, alleviating immunosuppression would improve the body’s own anti-tumor activity [74].”
Background
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
Anderson, T. S., McCormick, A. L., Piersall, S. L., Okpalanwaka, I. F., & Lowe, D. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.009 · Cited by 32
Automated, Miniaturized, and Integrated Quality Control-on-Chip (QC-on-a-Chip) for Cell-Based Cancer Therapy Applications
Wartmann, D., Rothbauer, M., Kuten, O., Barresi, C., Visús, C., Felzmann, T., & Ertl, P. (2015) · Frontiers in Materials · doi:10.3389/fmats.2015.00060 · Cited by 33
“In addition to the Nobel prize in Physiology and Medicine awarded in 2011 for discovery of DCs role in the immune system, latest advances in DC-based cancer immunotherapy were recently selected by Science as the breakthrough of the year 2013 (Couzin-Frankel, 2013).”
Background
Sympathetic‐mediated activationversussuppression of the immune system: consequences for hypertension
Case, A. J., & Zimmerman, M. C. (2015) · The Journal of Physiology · doi:10.1113/jp271516 · Cited by 32
“Altering T-lymphocyte function through immunotherapy is primarily achieved through the binding of either agonist or antagonist antibodies to various co-stimulatory surface molecules used in the normal regulation of T-lymphocyte activation (Couzin-Frankel, 2013).”
Background
Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes
Marino, N., Illingworth, S., Kodialbail, P., Patel, A. P., Calderón, H., Lear, R., Fisher, K., CHAMPION, B. R., & Brown, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177810 · Cited by 33
An Overview of Cancer Immunotherapeutic Strategies
Wahid, B., Ali, A., Rafique, S., Waqar, M., Wasim, M., Wahid, K., & Idrees, M. (2018) · Immunotherapy · doi:10.2217/imt-2018-0002 · Cited by 33
The Role of Artificial Intelligence in Deciphering Diet–Disease Relationships: Case Studies
Cohen, Y., Valdés‐Mas, R., & Elinav, E. (2023) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061121-090535 · Cited by 33
Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
Wang, S., & Khan, F. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310684 · Cited by 31
Biomimetic “Gemini nanoimmunoregulators” orchestrated for boosted photoimmunotherapy by spatiotemporally modulating PD-L1 and tumor-associated macrophages
Huang, H., Li, N., Wei, X., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.005 · Cited by 31
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy
Ascierto, M. L., Melero, I., & Ascierto, P. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00152 · Cited by 31
“The field is now investigating the role of novel approaches to be used either alone or in combination, such as (1) the blockade of lymphocyte activation gene 3 (LAG3), which normally stimulates Treg cells and inhibits CD8+ effector T cells through its interaction with MHC class II molecules and (2) T-cell membrane pro…”
BackgroundMethod
Herbal Compound Songyou Yin and Moderate Swimming Suppress Growth and Metastasis of Liver Cancer by Enhancing Immune Function
Zhang, Q., Meng, X.-T., Jia, Q., et al. (2015) · Integrative Cancer Therapies · doi:10.1177/1534735415622011 · Cited by 31
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute
Mellman, I., Hubbard-Lucey, V. M., Tontonoz, M. J., Kalos, M. D., Chen, D. S., Allison, J. P., Drake, C. G., Levitsky, H., Lönberg, N., van der Burg, S. H., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0045 · Cited by 31
“Indeed, cancer immunotherapy is increasingly recognized as a "breakthrough" approach, one with the potential to offer long-term, durable responses to patients with advanced cancer (2).”
Background
Stochastic modeling of tumor progression and immune evasion
George, J. T., & Levine, H. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.09.012 · Cited by 27
“However, there have been significant advances made most recently in targeted and immune therapeutic strategies (Couzin-Frankel, 2013).”
Background
Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non–Small Cell Lung Cancer
Li, H., Sun, Y., Yu, J., Liu, C., Liu, J., & Wang, Y. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.064 · Cited by 31
Method for the Instant In-Flight Manufacture of Black Phosphorus to Assemble Core@Shell Nanocomposites for Targeted Photoimmunotherapy
Nguyen, H. T., Byeon, J. H., Phung, C. D., et al. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b04632 · Cited by 31
Impact of N6-methyladenosine (m6A) modification on immunity
Elsabbagh, R. A., Rady, M., Watzl, C., Abou‐Aisha, K., & Gad, M. Z. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00939-8 · Cited by 33
Immunotherapy approaches for hematological cancers
Lanier, O. L., Pérez‐Herrero, E., Andrea, A. P. D. ’., Bahrami, K., Lee, E. Y. P., Ward, D. M., Ayala-Suárez, N., Rodríguez-Méndez, S. M., & Peppas, N. A. (2022) · iScience · doi:10.1016/j.isci.2022.105326 · Cited by 36
Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy
Wu, Y.-H., Chen, R.-J., Chiu, H., Yang, L., Wang, Y., Chen, Y., Yeh, Y.-L., Liao, M., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.77233 · Cited by 32
Dendritic cell-based vaccine for pancreatic cancer in Japan
Okamoto, M. (2016) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v7.i1.133 · Cited by 31

Authors: Couzin-Frankel, J.
Corresponding author: Couzin-Frankel, Jennifer
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-12-20
Volume: 342
Issue: 6165
Pages: 1432-1433
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.342.6165.1432
OpenAlex: W2209812019
Cited by: 2,051
References: 0
Citations by year: 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
FWCI: 73.49
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
MeSH terms: Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks